Department of Life Sciences, Central University of Tamil Nadu, Thiruvarur, India.
Front Cell Infect Microbiol. 2021 Mar 11;11:590874. doi: 10.3389/fcimb.2021.590874. eCollection 2021.
Gut microbiome alterations may play a paramount role in determining the clinical outcome of clinical COVID-19 with underlying comorbid conditions like T2D, cardiovascular disorders, obesity, etc. Research is warranted to manipulate the profile of gut microbiota in COVID-19 by employing combinatorial approaches such as the use of prebiotics, probiotics and symbiotics. Prediction of gut microbiome alterations in SARS-CoV-2 infection may likely permit the development of effective therapeutic strategies. Novel and targeted interventions by manipulating gut microbiota indeed represent a promising therapeutic approach against COVID-19 immunopathogenesis and associated co-morbidities. The impact of SARS-CoV-2 on host innate immune responses associated with gut microbiome profiling is likely to contribute to the development of key strategies for application and has seldom been attempted, especially in the context of symptomatic as well as asymptomatic COVID-19 disease.
肠道微生物组的改变可能在决定合并有 T2D、心血管疾病、肥胖症等基础合并症的临床 COVID-19 的临床结果方面发挥重要作用。有必要通过采用组合方法（如使用益生元、益生菌和共生菌）来研究操纵 COVID-19 中肠道微生物组的方法。对 SARS-CoV-2 感染中肠道微生物组改变的预测可能有助于开发有效的治疗策略。通过操纵肠道微生物组来进行新型和靶向干预确实代表了针对 COVID-19 免疫发病机制和相关合并症的有前途的治疗方法。SARS-CoV-2 对与肠道微生物组分析相关的宿主固有免疫反应的影响可能有助于制定关键策略的应用，并很少被尝试，特别是在有症状和无症状 COVID-19 疾病的情况下。
